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Background: It was hypothesized that asthmatic patients with mutant alleles in the
leukotriene pathway should not respond to leukotriene receptor antagonists and the
concept of a tailored treatment is increasingly supported.
Methods: Sixty-one patients (mean age 24.9 years, range 14–52) with moderate persistent
asthma were clinical and immunological assess prior and after a 6-month treatment with
montelukast. Tandem repeat polymorphisms were genotyped in the promoter (147 to
176) of 5-lipoxygenase gene (ALOX5).
Results: Thirty-two patients (52.5%) were homozygous for the five repeats allele; 17
(27.9%) were heterozygous (4/5 repeats) and 12 (19.7%) were homozygous for 4/4 repeats.
After the montelukast treatment decrease number of asthma exacerbations, improvement
of FEV1 and decreased use of b2 agonists was observed in patients with 5/5 or 4/5 repeats.
Conversely, the patients with 4/4 repeats genotype did not modify these data after
treatment.
Conclusions: It was confirmed that ALOX5 promoter polymorphisms have a clear influence
in montelukast response in atopic moderate persistent asthma patients. The genetic study
could identify those patients most likely to respond to montelukast.
& 2008 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
; ALOX5, 5-lipoxygenase gene; CysLT, cysteinyl leukotriene; FEV1, forced expiratory volume in the 1 s;
eptor antagonists.
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Leukotrienes (LTs) are a family of lipid mediators with a
crucial role in the inflammation.1 5-lipoxygenase (5-LO)
catalyses the conversion of arachidonic acid into LTA4, that
afterwards will be transformed to LTB4 or cysteinyl-LTs
(CysLTs). In this process, 5-LO and its activating protein
(FLAP) act as limiting enzymes.2 There are two types of LTs:
LTB4, a potent chemotactic mediator of inflammation, and
the CysLTs group, including LTC4, LTD4 and LTE4, all of them
powerful bronchoconstrictors, therefore playing a key role
in the pathophysiology of asthma and other inflammatory
diseases. The development of LT receptor antagonists
(LTRAs), such as montelukast or zafirlukast, represented an
important step towards the control of those diseases. Due to
their anti-inflammatory and anti-bronchoconstrictor proper-
ties, these drugs improve lung function parameters, such as
forced expiratory volume in the 1 s (FEV1) or peak flow,
reduce bronchial hyperresponsiveness and decrease the
number of asthma exacerbations, tapering the use of
inhaled corticosteroids which are the cornerstone of asthma
control. However, the patients show a widely variable
response to LTRAs treatment, fact that has been attributed
to genetic factors in 60% of the cases.3 The variance in genes
coding enzymes of the LTs synthesis cascade, such as 5-LO,
FLAP and LTC4 synthase, could be the explanation of this
different response to LTRAs.4
5-LO is coded by the ALOX5 gene that has a tandem
repeat polymorphism within the transcription factor-binding
region at position 147 to 176, of its promoter, a region
which is able to regulate gene transcription. Human cell
lines containing other than the five tandem Sp1 repeats
allele in the promoter region of ALOX5 seems to show a low
activity in the promoter-reporter activity.5 A previous study
performed with ABT-761, a direct inhibitor of 5-LO, showed
that patients with at least one wild-type allele (five tandem
repeats) had better response to this drug than patients
bearing only mutant alleles (other than five repeats).6 Based
on this finding, it was hypothesized that LTs are not
responsible for airway obstruction in the patients who fail
to respond to ALOX5 inhibition. According to this model,
asthmatic patients with only mutant alleles should not
respond to LTRAs drugs such as montelukast.6
The present paper shows the influence of the polymorph-
ism repeats variance of ALOX5 gene on the response to the
treatment with montelukast, being evaluated by FEV1,
number of asthma attacks and need of rescue medication.Figure 1 ALOX-5 genotyoing. Line 1: known 4/5 heterozygote
used as a control. Line 2: molecular weight marker. Line 3:
sample with genotype 5/4. Lines 4, 5, 7 and 8: samples with
genotype 5/5. Lines 6 and 9. samples with genotype 4/4.Patients and methods
The trial was designed as a prospective study and the aim
was to study the response to montelukast in atopic
asthmatic patients according to their ALOX-5 genotype.
The Ethical Committee of the Faculty of Medicine of
Valladolid approved the study.
Patients: A total of 61 patients (29 males) with a mean
age of 24.9 years (range 14–52) were included in the study.
All patients suffered moderate persistent asthma according
to the GINA guidelines,7 had serum IgE levels greater than
100 IU/mL, one or more positive prick test to aero-allergens
and received budesonide (500 mg/12 h) and b2 agonist ondemand. Despite this treatment, they had suffered episodes
of cough and/or wheezing during the last 2 years. No patient
was treated with oral steroids. Treatment with montelukast
was initiated as an add-on therapy given the inefficient
control of the disease.
The following data were collected prior and after the
6-month treatment period with montelukast: FEV1 in % of predicted.
 Number of puffs of short acting b2-agonist per day (puffs/
24 h) during the last month.
 Number of exacerbations. The exacerbations were
defined as a decrease in peak expiratory flow rate in
the morning of at least 25% compared with baseline.8
Blood sample was taken at the time of treatment
instauration and sent to the laboratory for genotyping.
After 6-month treatment period with montelukast, current
FEV1, consumption of b2 agonists and exacerbations in the
last month were recorded. All clinical data were recorded by
the same physician ignoring the genotype of the patients.
Controls: Sixty-one matched control patients were
genotyped in order to compare their allelic and genotypic
frequencies with the group of patients.
Genotyping: The ALOX-5 repeat polymorphisms study was
performed by hot-start polymerase chain reaction of an
amplicon containing the polymorphic region. The reaction
generates a 274 bp fragment (wild-type allele). Given that
GC rich region polymorphisms are difficult to genotype, the
GC-Rich PCR System (Roche Diagnostic GmbHs, Manheim,
Germany) was used. The amplicons were analysed in 6%
polyacrylamide gels (Figure 1). The primers used were:
forward 50 AGG AAC AGA CAC CTC GCT GAG GAG AG 30; and
reverse 50 GAG CAG CGA GCC CCG GGA GCC TCG GC 30. The
PCR protocol was: initial denaturalization 5min at 94 1C
followed by 30 cycles of 30 s at each of the following
temperatures: 94, 64 and 72 1C. A final incubation of 7min
was carried out at 72 1C.9 In order to avoid misinterpreta-
tions, the genotype were analysed blind with regard to
clinical data.
Data analysis: Improvements in FEV1, asthma exacerba-
tions (last month) and use of b2 agonist (puffs/day, last
month) achieved during the treatment period were com-
pared between patients homozygous for the allele with four
tandem repeats within ALOX5 promoter (4/4) and patients
with other genotypes (5/5 and 5/4). Two-sided Wilcoxon test
was used to establish the significance of differences
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5/5). This test was chosen because it is more powerful than
parametric tests for small groups.Results
Thirty-two patients (52.5%) were homozygous for the five
repeats allele; 17 (27.9%) were heterozygous, and the
remaining 12 (19.7%) were homozygous for the 4/4 repeats.
In the control group, the distribution was as follows: 42
(68.8%) five repeats homozygous, 12 (19.7%) heterozygous
and 7 (11.5%) 4/4 homozygous. The number of carriers of
the allele with four repeats was higher in the group of
asthma patients, but the difference did not reach statistical
significance with p ¼ 0.1712.
Before treatment, no clinical differences were found
among the three groups (Table 1). Conversely, the values
obtained after the 6-month treatment period with monte-
lukast were statistically significants, the worst data for all
variables were found in the group 4/4 tandem repeats
homozygous group. The response of heterozygous (4/5
repeats) patients was similar to the response of reference
group (5/5 repeats), except for the b2-agonists use, which
show intermediate values between both homozygous
groups, although clearly better than those of the 4/4
patients (Table 1).
Given that patients with genotypes 5/5 and 4/5 showed
similar response to montelukast, we grouped together these
patients and compared their response with the group of
patients homozygous 4/4.
There were neither demographic (age and sex) differ-
ences nor regarding to serum IgE levels or sensitisation to
aero-allergens (pollen and dust mites) measured by means
of prick test among both genotypic groups (Table 2).
Moreover, both compared groups showed similar clinical
features (FEV1, number of puffs of acting b2-agonist per day
during the last month and number of exacerbations) before
therapy (Figure 2 and attached table).
After the LTs treatment period, patients with 4/4 repeats
allele had 1.88 (SD ¼ 0.92) rate of asthma exacerbations inTable 1 Severity of asthma before and after 6-months treatm
ALOX5 genotype (5/5) (n ¼ 32)
Sex distribution (M/F) 15/17
Age (SD) 27.0 (13.8)
IgE in KUI/L (SD) 649.8 (473.3)
IgE rank 180–2300
Exacerbations in the last month mean (SD)
Before 4.7 (2.7)
After 0.4 (0.2)
FEV1 mean (SD)
Before 82% (8.1)
After 93% (7.3)
Puffs/24 h mean (SD)
Before 6.9 (3.0)
After 2.2 (1.8)the last month, with a mean reduction of 1.33 (SD ¼ 1.22),
whereas for cases with at least one five repeat allele was 0.4
(SD ¼ 0.21) exacerbations with a reduction of 4.41
(SD ¼ 2.76), a very significant difference (p ¼ 0.001). The
change in FEV1 was also more favourable in the group with at
least a five repeats: 93% (SD ¼ 7.0) with an increase of 8.6%
(SD ¼ 7.61) versus 80% and reduction of 1.4% (SD ¼ 8.04)
(p ¼ 0.0006). Finally, the 4/4 repeats group needed more b2
rescue medication: 5.1 (SD ¼ 2.84) with a reduction of 0.55
(SD ¼ 1.66) versus 2.9 (SD ¼ 2.77) and a reduction of 4.3
(SD ¼ 3.42) in the 5/5 repeats group (p ¼ 0.0011).Discussion
The efficacy of asthma treatment depends on the control of
environmental factors and also on pharmacological therapy.
Nowadays, increasing evidence is supporting the concept of
a tailored treatment for each patient. To reach this
objective, an exact knowledge of genetic influences on
drug response would be necessary.10,11 It is estimated that
up to 70% of the variability of the response to asthma
treatment is due to genetic conditions. Some authors
previously reported the influence of the A-444C SNP of the
LTC4 synthase gene to the response to CysLTR inhibitors,12,13
and a more recent study had discovered a better response to
montelukast in patients bearing the less frequent genotypes
of the MRP1 (rs119774) and ALOX5 (rs2115819).14
The allele with five tandem repeats (wild type) was the
most frequently found in our study in agreement to other
reports,6,9 the allelic frequency was 0.664 and the
frequency of homozygous patients was 0.525. This poly-
morphism had been associated to some asthma phenotypes
such as the severity,15 but never to asthma susceptibility. In
addition to five and four repeats, three and six repeat alleles
have been occasionally reported in some papers, but we did
not find them in the present study.
Prior to the LTRAs treatment period no significant
difference was present with respect to FEV1, b2 agonist
use, and exacerbation rate, between patients carrying or
not the five repeats allele. Conversely, after the 6-monthent with montelukast.
(5/4) (n ¼ 17) (4/4) (n ¼ 12)
8/9 6/6
27.9 (13.19) 23.3 (8.7)
556.8 (554.3) 622.2 (511.7)
290–2000 240–2000
5.0 (2.5) 3.22 (1.0)
0.4 (0.2) 1.88 (0.9)
85% (7.0) 81% (13.5)
92% (6.9) 80% (9.8)
7.8 (3.0) 6.1 (1.6)
4.0 (3.9) 5.1 (2.8)
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Table 2 Age and sex distribution, IgE levels and sensitisation to aerorallergens of patients homozygous 4/4 and patients with
at least one allele with five tandem repeats within the transcription factor-binding region of ALOX5 gene.
Male/female Age IgE (IU/mL) Prick test
Pollen Dust mites Both
4/4
Mean 6/6 23.33 622.22 10 (83.3%) 3 (25%) 1 (8.3%)
SD 8.75 511.68
5/4+5/5
Mean 23/26 27.21 625.34 44 (89.8%) 11 (22.4%) 6 (12.2%)
SD 13.23 479.13
Before therapy
After therapy
Exacerbations FEV1 (%) B2 adrenergicPuffs / 24h
Exacerbations FEV1 (%) B2 adrenergicPuffs / 24h
7
6
5
4
3
2
1
0
5/5+5/4 4/4 5/5+5/4 4/4 5/5+5/4 4/4
100%
95%
90%
85%
80%
75%
70%
10
9
8
7
6
5
4
3
2
1
0
P=n.s.P=n.s.P=n.s.
7
6
5
4
3
2
1
0
5/5+5/4 4/4 5/5+5/4 4/4 5/5+5/4 4/4
100%
95%
90%
85%
80%
75%
70%
10
9
8
7
6
5
4
3
2
1
0
P=0.0011P=0.0006P=0.001
BEFORE THERAPY
Exacerb. FEV1 (%) B2 / 24h
AFTER THERAPY
Exacerb. FEV1 (%) B2 / 24h
3.22 81% 6.11
0.97 13% 1.62
4.76
2.59 8%
83% 7.13
3.00
0.39
0.59
93%
7%
2.71
2.95
1.89
0.93 10%
80% 5.56
2.40
4/4 mean
SD
mean
SD
5/4+5/5
Figure 2
J.J. Telleria et al.860treatment with LTRAs, patients with at least one set of five
repeats showed better clinical evolution outcomes than
patients with 4/4 repeat alleles. In fact, among this lastgroup of patients, the average response was small or absent.
The differences between the two groups were very high
despite the small sample size.
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differences between wild type homozygous (5/5 repeats)
and heterozygous (4/5 repeats) suggesting that the wild-
type allele would be dominant, at least for the studied
phenotypes.
Classically, three different mechanisms have been said
to be involved in the influence of polymorphisms to the
therapy response: (a) variations affecting drug metabolism,
(b) variations related to mechanisms leading to adverse
effects, and (c) variations in the therapeutic target or in the
pathways activated by it.17
Our results are similar to other ones reported by Drazen
et al.6 but they observed the correlation between the
response to an ALOX5 inhibitor and the tandem repeat
polymorphism in the promoter of the same gene. This fact is
consistent with early studies supporting that addition and
deletion variants in the ALOX5 gene promoter diminished
the activity of promoter–reporter in vitro.5 Nevertheless, a
later study supported that some mutant variants of the
ALOX5 gene could also up-regulate the expression of this
gene.14
ALOX-5 and montelukast are not directly related, since
5-LO initiates the LT synthesis pathway and montelukast is
an antagonist of the receptors on which final products of the
pathway, namely the CysLTs, exert their actions. Bearing in
mind that ALOX-5 repeat polymorphism is a transcription
factor binding site which modulates transcription of the
reporter gene5 and thus the conversion of arachidonic acid
into LTA4, it may be expected that patients with 4/4 repeat
have a limited ability to initiate the cascade of LT synthesis
and it could be hypothesized that in these patients LTs would
probably not contribute much to the physiopathology of the
asthma and thus their inhibition would be of very limited
efficacy. Asthmatic patients could then be classified as
LT-dependent, who would respond to LT pathway inhibitors,
and LT-independent, who would not respond to those drugs.
The importance of repeat polymorphism in the ALOX5
promoter on the response to LTRAs is confirmed. More
polymorphisms related to the synthesis of LT could also be
involved in the treatment response to LT inhibitors, but
likely, the relative frequencies of those polymorphisms
widely vary among different populations.
From our data and given the frequency of allele 4 in our
population, we should expect a ratio of bad responders to LT
receptor inhibitors ranging between 12.3% and 18.9%
(CI ¼ 95%). This ratio is not age or sex dependent, but could
be higher in patients with moderate or severe asthma.15
Conflict of interest statement
The authors declare that none of them have any financial or
another sort of conflict of interest in relation to this study
that may influence their interpretation of the results.
Acknowledgments
This work has been partially sponsored by grants of Instituto
de Salud Carlos III (PI05/1746) and Fundacion Sociedad
Espan˜ola de Alergia e Inmunologı´a Clı´nica (2005).References
1. Drazen JM, Israel E, O’Byrne PM. Treatment of asthma with
drugs modifying the leukotriene pathway. N Engl J Med
1999;340:197–206.
2. Woods JW, Evans JF, Ethier D, Scott S, Vickers PJ, Hearn L, et al.
5-lipoxygenase and 5-lipoxygenase-activating protein are loca-
lized in the nuclear envelope of activated human leukocytes.
J Exp Med 1993;178:1935–46.
3. Drazen JM, Silverman EK, Lee TH. Heterogeneity of therapeutic
responses in asthma. Br Med Bull 2000;56:1054–70.
4. Hall IP, Sayers Y. Pharmacogenetics and asthma: false hope or
new dawn? Eur Resp J 2007;29:1239–45.
5. In KH, Asano K, Beier D, Grobholz J, Finn PW, Silverman EK,
et al. Naturally occurring mutations in the human 5-lipoxygen-
ase gene promoter that modify transcription factor binding and
reporter gene transcription. J Clin Invest 1997;99:1130–7.
6. Drazen JM, Yandava CN, Dube L, Szczerback N, Hippensteel R,
Pillari A, et al. Pharmacogenetic association between ALOX5
promoter genotype and the response to anti-asthma treatment.
Nat Genet 1999;22:168–70.
7. Masoli M, Fabian D, Holt S, Beasley R, Global Initiative for
Asthma (GINA) Program. The global burden of asthma: execu-
tive summary of the GINA Dissemination Committee report.
Allergy 2004;59:469–78.
8. Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O’Byrne P,
Barnes PJ, et al. Effect of inhaled formoterol and budesonide on
exacerbations of asthma. N Engl J Med 1997;337:1405–11.
9. Sayers I, Barton S, Rorke S, Sawyer J, Peng Q, Beghe B, et al.
Promoter polymorphism in the 5-lipoxygenase (ALOX5) and
5-lipoxygenase-activating protein (ALOX5AP) genes and asthma
susceptibility in a Caucasian population. Clin Exp Allergy
2003;33:1103–10.
10. Leff AR. Regulation of leukotrienes in the management of
asthma: biology and clinical therapy. Annu Rev Med 2001;
52:1–14.
11. Wechsler ME. Managing asthma in the 21st century: role of
pharmacogenetics. Pediatr Ann 2006;35:664–9.
12. Szczeklik A, Mastalerz L, Nizankowska E, Sanak M. Myocardial
ischemia possibly mediated by cysteinyl leukotrienes. J Allergy
Clin Immunol 2002;109:572–3.
13. Sampson AP, Siddiqui S, Buchanan D, Howarth PH, Holgate ST,
Holloway JW, et al. Variant LTC(4) synthase allele modifies
cysteinyl leukotriene synthesis in eosinophils and predicts
clinical response to zafirlukast. Thorax 2000;55(Suppl 2):
S28–31.
14. Lima JJ, Zhang S, Grant A, Shao L, Tantisira KG, Allayee H, et al.
Influence of leukotriene pathway polymorphisms on response to
montelukast in asthma. Am J Respir Crit Care Med 2006;173:
379–85.
15. Kalayci O, Birben E, Sackesen C, Keskin O, Tahan F, Wechsler
ME, et al. ALOX5 promoter genotype, asthma severity and LTC
production by eosinophils. Allergy 2006;61:97–103.
16. Fowler SJ, Hall IP, Wilson AM, Wheatley AP, Lipworth BJ.
5-Lipoxygenase polymorphism and in-vivo response to leuko-
triene receptor antagonists. Eur J Clin Pharmacol 2002;58:
187–90.
17. Sayers I, Hall IP. Pharmacogenetic approaches in the treatment
of asthma. Curr Allergy Asthma Rep 2005;5:101–8.
